At the end of January, the National Pharmaceutical Council issued a permit for Sequoya Europe for the production, processing, and distribution of Δ-9-THC derived from the processing of hemp.

The decision was issued on the basis of an audit carried out in November 2020. The positive decision of the National Pharmaceutical Council the highest quality standards that apply in the Sequoya Europe production plant. We are glad that our laboratory and production practice has been approved by such an important authority. Thanks to this decision, we have reached a milestone on the way to obtaining full GMP PHARMA accreditation and we know that we are going in the right direction – says Angelika Pawilkowska, Co-Founder and Operations Director at Sequoya Europe.

Sequoya Europe is one of the most advanced manufacturers of hemp extracts in Europe. The area of the company’s activity includes research and development, quality control, production, and distribution of hemp products. Sequoya specializes in wholesale and private label production of hemp products, such as CBD full and broad spectrum oils, cannabinoid isolates (CBD, CBG), CBD distillates, CBD e-liquids. Sequoia’s customers are small and medium-sized companies as well as the world’s largest brands from the cosmetics, food, nutraceutical, and pharmaceutical industries. The quality of Sequoy’s products is confirmed by the Food Safety and Hygiene Certificate – HACCP, GMP Food Grade Certificate, and also by independent laboratory tests.